FILE:ABT/ABT-8K-20100701075800.txt.gz
EVENTS:	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
TEXT:
ITEM: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
 
 
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
           
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
           
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
           
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
           
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
Item 5.02  Departure of Directors or Certain Officers.
 
Olivier Bohuon, Executive Vice President, Pharmaceutical Products, has informed Abbott that he will retire from the company. He is expected to shortly announce his plans to accept another opportunity.  Effective July 1, 2010, Richard A. Gonzalez has been named Executive Vice President, Pharmaceutical Products, succeeding Mr. Bohuon. Mr. Gonzalez will serve in this role on an interim basis.
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


